The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study-Reference-Cited by-同舟云学术

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study

Published:2012-12 Issue:6 Volume:14 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Rhiem Kerstin,Engel Christoph,Graeser Monika,Zachariae Silke,Kast Karin,Kiechle Marion,Ditsch Nina,Janni Wolfgang,Mundhenke Christoph,Golatta Michael,Varga Dominic,Preisler-Adams Sabine,Heinrich Tilman,Bick Ulrich,Gadzicki Dorothea,Briest Susanne,Meindl Alfons,Schmutzler Rita K

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr3369.pdf

Reference26 articles.

1. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck RT, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.

2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Gene. 2003, 72: 1117-1130. 10.1086/375033.

3. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006, 24: 2437-2443. 10.1200/JCO.2005.02.7888.

4. Pierce LJ, Haffty BG: Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol. 2011, 21: 43-50. 10.1016/j.semradonc.2010.08.008.

5. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation Carriers. J Clin Oncol. 2009, 27: 5887-5892. 10.1200/JCO.2008.19.9430.

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of knowledge and knowledge gain after decision aid use among women with BRCA1/2 pathogenic variants;Patient Education and Counseling;2024-07

2. Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline;Journal of Clinical Oncology;2024-02-10

3. Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study;Breast Cancer Research;2024-01-22

4. Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial;BMC Medical Informatics and Decision Making;2023-10-16

5. Prognosis and Decision-making Analysis of Contralateral Prophylactic Mastectomy among female patients with stage 0–III unilateral breast cancer in Chinese population: a retrospective cohort study;2023-08-22